Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Alkem Laboratories is a top-tier Indian formulations company with an acute-therapy-heavy domestic portfolio led by anti-infective mega-brands Clavam and Pan/Pan-D, plus gastro, pain and vitamins franchises, and a growing chronic segment. It also sells generics in the US and other international markets and manufactures APIs. Revenue is dominated by India branded generics, where its brands rank among the country's largest by prescriptions.
Among India's top five pharma companies by domestic sales, with leadership in anti-infectives.
Alkem Laboratories Ltd. is a constituent of NIFTY 200, NIFTY 500, NIFTY HEALTHCARE, NIFTY MIDCAP 100, NIFTY MIDCAP 150, NIFTY MIDCAP 50, NIFTY PHARMA. See where it sits on the market heatmap →
Consolidated annual figures taken from Alkem Laboratories Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 192.51 | 181.11 | 150.19 |
| Book value / share (₹) | 1,200.25 | 1,040.04 | 896.23 |
| Return on equity | 16.0% | 17.4% | 16.8% |
| Return on capital employed | 16.3% | 15.7% | 16.8% |
| Operating margin | 17.8% | 16.6% | 15.4% |
| Net margin | 16.0% | 17.1% | 14.3% |
| EBITDA | ₹3,005 Cr | ₹2,512 Cr | ₹2,245 Cr |
| Free cash flow | ₹1,346 Cr | ₹1,237 Cr | ₹1,689 Cr |
| Total debt | ₹1,624 Cr | ₹1,063 Cr | ₹1,214 Cr |
| Debt to equity | 0.11 | 0.09 | 0.11 |
| Interest coverage | 16.3 | 17.7 | 17.3 |
| Current ratio | 2.55 | 2.73 | 2.61 |
| Shares outstanding | 11,95,50,000 | 11,95,50,000 | 11,95,50,000 |
Open the full income statement, balance sheet and cash flow for ALKEM →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.